Leukemia
Leukemia is a type of cancer that starts in blood-forming tissue such as bone marrow and causes abnormal or aberrant blood cells to be produced in large amounts and enter the bloodstream.
In most types of leukemia, the abnormal cells are white blood cells (WBCs). WBCs, which are an important player in our defense system against various types of infections, may be produced in excessive amounts or may be unable to work properly. In both cases, it results in the weakening of our immune system.
As leukemia is not a solid tumour, they generally do not metastasize but may be life-threatening nonetheless as they weaken patients’ immune systems and overall health and lead to infections, anemia, and easy bleeding.
Although leukemia is the tenth most diagnosed type of cancer, it is the seventh deadliest amongst Canadian adults. It has been estimated that for the year 2011, 5,000 new leukemia diagnoses would be made in Canada and that 2,500 Canadians would die from the disease; 60% men for 40% women. The relative 5-year survival rate for leukemia in Canada is estimated at 55%.
Amongst Canadian children and young adults, leukemia is the most common and the deadliest type of cancer. However, its relative 5-year survival rate for children is estimated at 84%.
This section is still in construction. Please come back shortly for a more complete description of the disease.
Research projects focused on this topic
- Functional comparisons of the antisene proteins encoded by the various HTLV viruses
- A shed soluble form of CD200 has prognostic and therapeutic implications in CLL
- HOX11 transcriptional regulation of target genes in T-ALL
- Molecular and functional characterization of an AHI-1-BCR-ABL interaction complex in chronic myeloid leukemia
- Overcoming Imatinib resistance in CML with combination therapy of new ABL and ILK inhibitors
- Preclinical validation of ALL relapse predisposing variants in DHFR and TS genes
- Developing a B-cell model for leukemia induction by E2A-PBX1
- Role of the myeloid transcription factor Gfi1 and the Gfi136N variant in human acute myeloid leukemia
- Characterization of ETV6 gene targets
- Investigation of a new clonal event: Chromosome-arm-specific telomere elongation in acute lymphoblastic leukemia (ALL)
- Identification of novel biomarker in multiple myeloma therapy resistance
- Regulation of the mutagenic capacity of the antibody diversification enzyme AID by Hsp90
- Regulatory T cell therapy for graft versus host disease
- Role of the transcription factor Gfi1 and the Gfi136N variant in Acute myeloid leukemia (AML)
- Role of Cbl in Juvenile Myelomonocytic Leukemia









